Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Medical Device Venture Lazzaro Medical Secures $1M from Northwell Heath


“TBM is estimated to be present in half of the nation’s 16 million COPD patients and previous treatment was worse than the disease. The LM Scaffold System™ will reduce operating times by an estimated 50% and shorten patient recovery time from months to weeks.” Dr. Richard Lazzaro

Lazzaro Medical, a Boulder-based medical device company seeking to help millions of people suffering from Tracheobronchomalacia (TBM), received a $1 million strategic investment from Northwell Health, New York State’s largest healthcare provider.

The investment aims to support restoring healthy breathing in previously untreated patients while addressing a large untapped market with Lazzaro Medical’s Robotic Minimally Invasive Tracheal Repair (MITR™) surgery using its newly patented LM Scaffold System™. Pioneered by world-renowned, robotic thoracic surgeon Dr. Richard Lazzaro, the system is designed to increase safety and decrease time to perform this procedure.

“In the United States, TBM is estimated to be present in half of the nation’s 16 million COPD patients. Previous treatment was worse than the disease for many potential patients,” said Dr. Lazzaro, Co-Founder and Chief Medical Officer of Lazzaro Medical. “The LM Scaffold System™ will dramatically reduce operating times by an estimated 50% and shorten patient recovery time from months to weeks.”

The funding will be used to prepare the company’s 510K FDA submission and support its forthcoming commercial launch. Subsequent rounds will support Lazzaro Medical’s platform expansion, which includes a game-changing diagnostic endoscope, comprehensive training programs for thoracic surgeons and additional devices to further simplify the procedure.

“Dr. Lazzaro’s work is truly life-changing for so many people,” said Richard Mulry, President & CEO of Northwell Holdings. “We look forward to seeing the company’s progress and are delighted Northwell can play a part in supporting these efforts.”

With Northwell’s strategic investment, Lazzaro Medical has raised a total of $2 million from investors, including a $250,000 grant from the Global Business Development division of the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Accelerator Grant Program. Bolstering Lazzaro Medical’s remaining $3.5 million convertible note offering is an investment commitment from another strategic partner. These strategic partner investments help further validate Lazzaro Medical’s mission of helping people breathe better again.

“We’re thrilled to welcome this strategic investment from Northwell, a world-class leader driving innovation in patient outcomes and care,” said Rob Israel, Co-Founder and CDO of Lazzaro Medical. “We’ll be able to expedite our regulatory process and bring our LM Scaffold System™ solution to market more quickly while adding to our growing patent portfolio.”

Lazzaro Medical was founded in 2019 with a mission to help millions breathe easily again by bringing awareness to TBM as a largely under or misdiagnosed disease and offer a less invasive and risky repair option to those suffering from this degenerative condition that causes the collapse of the airway due to the softening of cartilage in the trachea.

ABOUT LAZZARO MEDICAL

Lazzaro Medical is a Boulder, Colorado-based medical device company on a mission to restore healthy breathing in millions of people suffering from tracheal and bronchial maladies with a transformative platform of life-changing, minimally-invasive, robotic procedures, devices, and diagnostics. Co-Founded by Dr. Richard Lazzaro, a world-renowned thoracic surgeon with 35 years of specialized expertise in minimally invasive and robotic thoracic surgery, the company’s platform is based off his groundbreaking firsts in robotic thoracic surgery and his leading the largest tracheobronchomalacia (TBM) programs in the nation. For more information on Lazzaro Medical, please visit Lazzaromed.com, or follow @Lazzaro Medical on LinkedIn.

ABOUT NORTHWELL HEALTH

Northwell Health is New York State’s largest health care provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 12,000 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 80,000 employees – 18,900 nurses and 4,900 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.

Share article on social media or email:



$2 Billion IVD Market Opportunity in Singapore, Malaysia and Indonesia: Kalorama Information


The market for IVDs in the three countries combined exceeds $1.9 billion dollars.

Per a recent Kalorama Information report, In Vitro Diagnostics (IVD) in Malaysia, Singapore and Indonesia, 2022. The market for IVDs in the three countries combined exceeds $1.9 billion dollars. This includes clinical tests for infectious disease, hematology, basic bloodwork, glucose and other conditions.

The impact of COVID-19 in the microbiology and virology markets has started declining since the beginning of 2022 in Malaysia, Indonesia, and Singapore. Regulatory bodies in all the three countries reduced their reliance on RT-PCR tests for accurate diagnosis of COVID-19 during the first quarter of 2022. Immunoassays that detect viral-specific IgG and IgM antibodies or antigens started gaining market share in 2021. Rapid antigen tests that allowed home-testing started gaining market share by the second half of 2021 and were accepted by the regulatory agencies for allowing travels within the respective countries. As the whole population received vaccinations, travel restrictions got relaxed further, which played a critical role in the declining of the demand for molecular as well as immunoassay testing for COVID-19.

Indonesia: Indonesia’s IVD market is the largest among the three countries, which is mainly due to the population of the country. The Singapore market, on the other hand, is large considering its population. This market benefits from the availability of expensive and advanced IVD systems. Malaysia also has advanced healthcare systems and due to its larger population, the IVD market size is larger than that of Singapore.

Singapore: Among these three countries, Singapore has established world class healthcare service capabilities in terms of infrastructure as well as skilled manpower. Though the population is less than 6 million, the Singapore market is attractive for IVD companies and it has become a medical tourism hub in the region. Indonesia, on the other hand, is a country with a huge population of about 275 million people. The country is taking significant steps to improve its healthcare infrastructure, which is offering considerable opportunities for IVD companies. The Malaysian market, with a population of about 32 million falls in between these two countries, both in terms of healthcare service capabilities and growth potentials.

Malaysia: The World Bank estimates Gross Domestic Product (GDP) of Malaysia to be $372.7 billion in 2021, which represents 0.03% of the world economy. The country reported 5.7% GDP growth in 2021 compared to the previous year. Malaysia offers some of the best healthcare services in Southeast Asia, and has been growing as a medical tourism destination, even though COVID-19 pandemic impacted this potential significantly during the past two years. The segment is recovering and is expected to see commendable growth in the coming years, especially since healthcare infrastructure has improved significantly during the pandemic, including in diagnostics and digital health capabilities.

Major global manufacturers of IVD tests market products in these three nations. Distributors with local expertise are often used. This is a partial list of distribution companies.

Share article on social media or email:

NCPDP Announces Pilot Launch of its National Facilitator Model to Strengthen Pandemic and Epidemic Preparedness & Response and Support Public Health Surveillance


NCPDP Logo

NCPDP announced today the pilot launch of its National Facilitator Model which can be used to provide real-time information on prescription, testing, immunization, and related data to pharmacies, prescribers and government agencies to aid in pandemic and epidemic response, proactive intervention and public health surveillance. The National Facilitator Model uses NCPDP standards widely used throughout the industry to ensure interoperability and real-time access to data nationwide and within providers’ existing workflows. In Phase 1 of the project, pharmacists will access, monitor and report COVID-19 vaccination series information to validate key capabilities of the model: (1) workflow-enabled efficiencies; (2) interoperability of data aggregated across different sites and state lines; and (3) real-time data access and update capabilities.

Organizations participating in the pilot include: STChealth as principle researchers and National Facilitator Registry with expertise in developing national vaccine registry standards, technology and intelligence; community pharmacists from Osborn Drugs, Discount Drug Mart and Sam’s HealthMart; file transfer services from QS1/Redsail and Change Healthcare; switch service file transfer by RelayHealth/CoverMyMeds; and patient record data integrity by Experian Health, using the Universal Patient Identifier (UPI), powered by Experian Health UIM and NCPDP Standards™ to assure that vaccination information is tied to the right individual.

“The COVID-19 pandemic and opioid epidemic exposed, among other things, gaps in care which were filled thanks to pharmacists, and challenges with the current public health infrastructure,” explained Lee Ann Stember, President & CEO of NCPDP. “And while there has been strong support for modernizing our public health infrastructure and eliminating data silos, pharmacists and other providers still lack access to comprehensive, real-time information from across the healthcare ecosystem at the point of care to help inform clinical decision making. The NCPDP National Facilitator Model aims to make that possible using the same interoperable industry standards that support pharmacists’ instant access to eligibility, pharmacy claim billing, prior authorization, and for prescribers to instantly transmit, change and discontinue prescriptions today. This pilot is vital; we simply cannot wait for the next epidemic to take action.”

Funding for the pilot project is provided by an NCPDP Foundation grant of $150,000 awarded to STChealth. The NCPDP Foundation grant is funded by the Lee Ann Stember Endowment; Founders Gift Donors FDB (First Databank) and GoodRx; and its general fund. Both STChealth and Experian Health have provided in-kind support and reduced fees to support the pilot.

Stember added, “I am personally and professionally invested in supporting the pilot of the National Facilitator Model. It has been available to deploy for nine years to help combat the opioid epidemic and provide prescribers and pharmacists with alerts of potential misuse or abuse before an opioid is even prescribed. The COVID-19 pandemic prompted application of the model to address all public health crises, beyond the opioid epidemic. There has been great support for the model amongst congressional leaders, industry associations and others across the healthcare industry. The private sector must move it forward and make it operational for widespread adoption and use for pandemic and epidemic response and public health surveillance.”

Michael Popovich, CEO of STChealth said simply, “It’s about time. Few have the opportunity to be in the right place at the right time to take on new health information challenges that will benefit this and future generations. STChealth is very grateful to play a small part in this initiative and for the leadership and vision at NCPDP and the participating project partners, all willing to take a risk and a step forward to bring improved health care to individuals.”

FDB President Bob Katter, who serves as patient safety chair for the NCPDP Foundation’s new National Advisory Council, said, “FDB is pleased to join NCPDP to help extend adoption of its National Facilitator Model. Managing the health of individuals and populations proactively, especially during a public health emergency, requires that clinicians and responding agencies have ready access to and the ability to share comprehensive, flexible, and intuitive medication data. Further, patient-specific health and medication data help identify at-risk patients and inform actionable next steps. The National Facilitator Model is a natural extension of our decades-long partnership with NCPDP through which we deliver trusted drug knowledge and interoperability capabilities to support healthcare professionals in carrying out their critical workflows.”

“GoodRx is a proud supporter of the NCPDP Foundation and the launch of Phase I of the National Facilitator Model. We believe it will bring the role of the pharmacist to the forefront for population health management and solidify their place in our communities – providing needed access to care,” said Frannie McGowan, CEO of Scriptcycle (a wholly owned subsidiary of GoodRx), and the NCPDP Foundation’s National Advisory Council Chair for Patient Access to Care.

About NCPDP

Founded in 1977, NCPDP is a not-for-profit, ANSI-accredited, Standards Development Organization with more than 1,500 members representing virtually every sector of the pharmacy services industry. Our diverse membership provides leadership and healthcare business solutions through education and standards, created using the consensus building process. NCPDP has been named in federal legislation, including HIPAA, MMA, and HITECH. NCPDP members have created standards such as the Telecommunication Standard and Batch Standard, the SCRIPT Standard for ePrescribing, the Manufacturers Rebate Standard and more to improve communication within the pharmacy industry. Our data products include dataQ®, a robust database of information on more than 80,000 pharmacies, resQ™, an industry pharmacy credentialing resource, and HCIdea®, an innovative prescriber database that provides continually updated information on more than 2.5 million prescribers. NCPDP’s RxReconn® is a legislative tracking product for real-time monitoring of pharmacy-related state and national legislative and regulatory activity. For more information about NCPDP Standards, Data Services, Products, Educational Programs and Work Group meetings, go online at http://www.ncpdp.org or call 480.477.1000.

Share article on social media or email:

Longitudinal Study of AI in Breast Density To Be Presented at RSNA


Onsite Women’s Health, a leading national provider of breast health services, announces with Whiterabbit.ai and Washington University in St. Louis the results of a longitudinal study of breast density using artificial intelligence (AI). RSNA (Radiological Society of North America) accepted the scientific abstract submitted by researchers from Onsite, Whiterabbit and Washington University in St. Louis for an oral presentation, titled: Artificial Intelligence and Consistency in Patient Care: A Large-Scale, Longitudinal Study of Breast Density Assessment at the 108th Scientific Assembly and Annual Meeting (Date/Time of Session: 11/28/2022 1:30-2:30 pm CT).

“Higher density breast tissue on mammograms means higher risk for breast cancer,” says Dr. Susan Holley, clinical director of Onsite Women’s Health and presenter of the abstract. “Therefore, breast density is an important variable to get right. We wanted to know if an AI tool could help us be right more often, over the long-term.”

“We are eager to share the findings of this large-scale retrospective study as it reveals fascinating trends about the assessment of breast density over time by radiologists and our AI software, WRDensity. We believe the consistent assessment of breast density is vital to more effective patient management that moves us towards the goal of precision medicine. I’m enthusiastic that new technologies may make a difference in this noble endeavor,” says Jason Su, Whiterabbit’s co-founder and chief technology officer. “We are grateful to have been able to partner with Onsite and Washington University in St. Louis to conduct this study. Their interest in our AI tool and engagement with us has and will continue to be critical to its ongoing development.”

The team hopes to expand upon this work to explore implications for supplemental screening, and how longitudinal changes in breast density might further inform our understanding of breast cancer risk.

“The diversity of our research team with representation from real world practice, industry, and academic researchers allows us to pursue really exciting and clinically relevant questions,” concludes Aimilia Gastounioti, assistant professor of Radiology and director of the Breast Image Computing Lab at Washington University in St. Louis. “The advent of AI is poised to change the delivery of health care dramatically in the near future. With academic researchers, physicians and industry partners working hand-in-hand, we can bring all our strengths together to look at questions that have big implications for breast imaging and patient care.”

About Onsite Women’s Health

Onsite Women’s Health is the leading provider of convenient breast health services, including 3D Tomosynthesis mammography screening and diagnostic services and screening breast ultrasound powered by an AI-driven strategy. Onsite partnerships support screening compliance by ensuring preventive breast care is convenient, accessible, and personalized to the individual risk profile of each patient. By utilizing advanced risk assessment tools, Onsite creates a personalized breast care plan for each patient applying the latest technology and expert review to each service. Onsite services increase patient satisfaction, improves breast health compliance, and serves as a revenue opportunity for our practice clients. They currently operate in 25 states with two more states being added soon. They have performed 1.5 million studies since 2013 and conducted 98,000 risk assessment exams since January 2018. For more information visit us at: http://www.onsitewomenshealth.com,

About Whiterabbit.ai

Whiterabbit.ai is an AI technology company with a mission to improve lives through earlier, more accurate cancer detection. A growing number of radiologists and healthcare providers are using Whiterabbit’s technology to improve patients’ experience with breast cancer screening. In addition to ACT, an AI-powered outreach service that helps improve compliance and get more women screened, Whiterabbit has developed two other product lines – WRDensity and WRRisk. WRDensity is an FDA-cleared artificial intelligence-driven software that helps radiologists better assess breast density. WRRisk, a clinical decision support software for risk assessment based on well-established breast cancer risk models, assigns a risk rating to a patient, and provides vital information to a physician to create a more personalized screening regimen with consistent follow-up and more accurate clinical diagnosis. Whiterabbit is headquartered in Santa Clara, California. For more about Whiterabbit, visit https://whiterabbit.ai/

About Washington University in St. Louis

The Washington University School of Medicine in St. Louis, consistently ranked in the top 10 medical schools in the United States by U.S. News & World Report and by funding from the National Institutes of Health (NIH), has a rich scientific history in basic, clinical, and translational research. The Breast Image Computing Lab at Washington University in St. Louis, led by Aimilia Gastounioti, conducts translational breast imaging research towards risk assessment, early diagnosis, and prognosis for breast cancer. Their research activities combine elements of computational breast imaging, AI, and informatics to build technologies with a potential for clinical impact in advancing breast cancer screening and prevention strategies. For more information, visit us at https://mir.wustl.edu/gastounioti-lab

Share article on social media or email:

Labroots Hosts 5th CRISPR Virtual Event on November 2nd, 2022


CRISPR, November 2, 2022

Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is delighted to announce its 5th annual CRISPR virtual event. The free, online event builds on previous years events and advances the conversations happening around sessions such as CRISPR Biology, CRISPR in Diagnostics, and CRISPR in Disease Therapy. This event will take place on November 2, 2022.

CRISPR 2022 promises to bring together thought leaders from academia, research scholars, top scientists, and industry experts from pharmaceutics and biotech from around the world to uncover promising approaches and advances in the field.

The educational agenda featuring distinguished speakers will showcase cutting-edge research in the discovery of new CRISPR-Cas systems, gene editing therapies, and other applications. Topics for discussion include key requirements of CRISPR reagents for preclinical and translational research, current and novel approaches to targeted gene editing, new molecular technologies for genome editing and cell control, innovative tools for efficient CRISPR-Cas genome engineering, CRISPR-based microfluidic biosensing systems for molecular diagnostics, detecting viruses with CRISPR, and so much more!

“The pandemic inspired our community to come together and harness our collective talents to create new classes of diagnostics and therapeutics for detecting and treating pathogens,” commented Planning Committee Member, James. J. Collins and Termeer Professor of Medical Engineering & Science, and Professor of Biological Engineering, MIT. “These innovative efforts brilliantly leveraged conceptual and technical advances in synthetic biology and CRISPR-based technologies, and we aim to highlight these successes in this timely conference.”

Key highlights encompass a keynote presentation discussing the mechanism of CRISPR-Cas13 systems and the engineering methods for nucleic acid detection, presented by Dr. Xue Sherry Gao, Ted N. Law Assistant Professor, Department of Chemical and Biomolecular Engineering at Rice University, followed by Dr. Can Dincer, Junior Research Group Leader, University of Freiburg, Department of Microsytems Engineering-IMTEK summarizing the fundamentals of CRISPR-powered biosensing during his keynote delivery titled, ‘CRISPR-Powered Multiplexed Biosensor for Point-of-Care Management of Infectious Diseases’ with Live Q&A.

“We’ve been working to design and engineer new platforms for viral detection since the COVID-19 pandemic started,” said Dr. Xue Sherry Gao, Assistant Professor in the Department of Chemical and Biomolecular Engineering at Rice. “Our focus is on platforms that can be used in low-resource setting areas when expensive PCR machines are not available. I would like to share with the audience our work on the identification of a flexible hairpin loop near CRISPR-Cas13’s active site. By inserting an RNA binding domain into that unique loop, greatly enhanced the activity of the Cas13 activity in detecting various viruses, including SARS-CoV-2. By coupling with an electrochemical sensor, our engineered Cas13 protein showed attomolar levels of activity without pre-amplification and complex handling of the viral samples.”

“Over last few years, we have witnessed great innovations and advances in the field of nucleic acid diagnostics driven by the unique features of the CRISPR/Cas technology,” said Dr. Can Dincer, Junior Research Group Leader at FIT & IMTEK, University of Freiburg. “In this keynote presentation, a CRISPR-powered multiplexed biosensing system capable of not only simultaneously detecting nucleic acids but also other molecules like drugs will be presented, as well as the current challenges and future perspectives of CRISPR-based biosensing will be discussed. I’m excited to share our research via Labroots’ unique virtual platform.”

“Our annual CRISPR virtual event has been a benchmark in the field and continues to highlight creative new CRISPR technologies and further progress genome engineering revolutionizing biological research while making groundbreaking inroads to therapies,” said Greg Cruikshank, Chief Executive Officer of Labroots. “We are delighted to host and produce this event for the scientific community to stay up to date on novel research and global trends in CRISPR biology.”

Produced on Labroots’ robust platform allowing the capability to connect seamlessly across all desktops and mobile devices, the interactive environment delivers a one-stop educational experience. Attendees will visit the lobby with leaderboard and gamification, an auditorium featuring live-streaming video webcasts with live attendee chats during scheduled presentations, an exhibit hall to interact with sponsors and view their products and technologies, a poster hall to explore data and engage in live chat conversations, and featuring a poster competition to give your research a competitive edge, and a networking lounge to make valuable connections with colleagues. By participating, there is a potential to earn up to 1 P.A.C.E. Continuing Education credit per presentation for a maximum of 30 credits.

To register for the event, click here. Join the online conversation and use the hashtag #LRcrispr. Follow @Genetics_LR on Twitter and @GeneticsandGenomics on Facebook to connect with our specialist Genetics & Genomics Writers and stay up to date with the latest Trending News in Genetics & Genomics. Now you can also join our professional community on LinkedIn by being a part of the Genetics & Genomics group!

About Labroots

Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Now, Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

Share article on social media or email:

Enter the GOLO Fall Inspirations Giveaway for the Opportunity to Win Great Prizes


Enter the GOLO Fall Inspirations Giveaway

Enter the GOLO Fall Inspirations Giveaway for the Opportunity to Win Great Prizes

This year, add a new fun activity to the fall schedule by entering the GOLO Fall Inspirations Giveaway.

GOLO, the wellness solutions company, understands that as the weather outside cools down, our excitement grows for classic fall activities like apple picking, getting lost in a corn maze, and nature hikes surrounded by colorful foliage. This year, add a new fun activity to the fall schedule by entering the GOLO Fall Inspirations Giveaway.

It’s easy, and entrants could win a special gift package including the GOLO for Life® Plan with one bottle of Release® dietary supplement, an AeroTrainer® exercise platform, a COSORI Air Fryer, and an Etekcity Fitness Tracker.

Here’s how to enter the Giveaway:

  • Between October 25, 2022, at 8:00 AM EST and November 29, 2022, at 11:59 PM EST, you can enter by submitting your name, email, and mailing address online here.
  • Include your favorite fall activity (for example – visiting a pumpkin patch)
  • Three winners will be selected at random from all eligible entries
  • Click here for full details

Wherever you are on your health and wellness journey, GOLO offers a range of innovative products designed to help, including the GOLO for Life Plan®, a game-changing nutritional approach to losing weight, and a healthy alternative to conventional dieting. The program includes GOLO Release® (an all-natural dietary supplement), access to personal coaches, and online tools. For more information on GOLO, please visit golo.com.

About GOLO

GOLO® products provide safe solutions to weight-loss and wellness while helping individuals transition to a healthier and sustainable lifestyle. GOLO has reached over two million people worldwide who now have a chance at healthy, sustainable, and affordable weight loss. For more information about the GOLO® for Life plan, visit golo.com or call 800-730-4656.

Share article on social media or email:

Lia Jamian, M.D. inducted into Palm Beach Medical Society’s “Physician Leadership Academy” class of 2022, team’s work project to improve access to Behavioral Health


News Image

Dr. Lia Jamian, MD

“This project is just a first step to address our group’s particular concerns regarding patient access to behavioral health services,” explains group project leader, Seneca Harberger.

The six doctors (Lia Jamian, M.D., Colette Brown-Graham, M.D., Seneca Harberger, M.D., Heather Johnson, M.D., Harish Madhav, M.D., and Vicki Norton, M.D.) worked with Karen Harwood and CEO Kelly Skidmore, from the PBC Medical Society, to identify this tangible problem. The team, composed of physicians from a range of specialties, noted that front-line doctors often struggle to find clear solutions for their patients’ behavioral health needs.

These issues arise, in part, from the growing shortage of available psychiatrists and therapists, especially during the pandemic, when the demand has been at an all-time high. The team also sought to understand what resources are available and how physicians could more efficiently guide their patients to these resources. While the team initially aimed to create a robust and reliable directory of services, they came to understand that this work is already being done by a great team at 211 of Palm Beach and the Treasure Coast (available at 211PalmBeach.org). They then shifted their goal to create a simple and easily accessible guide for physicians to use to rapidly address patients’ needs in the moment of clinical care.

While considering the needs of busy physicians, the team worked with community stakeholders and identified key questions that needed to be answered to connect a patient with the best behavioral health resources. The Palm Beach County physicians developed an algorithm, outlined in the flowchart below, to address three key areas of need. The first goal is to guide physicians to resources that are most helpful during a patient crisis, the second is to provide resources to support patients struggling to overcome significant barriers to care, and finally to provide a sustainable, reliable database of resources a patient can independently access, if not in a crisis or facing significant barriers.

Using a flowchart, the team created a simple handout (available at PBCMentalHealth.org) to help guide physicians and provide clear contact information for the appropriate resource. “This project is just a first step to address our group’s particular concerns regarding patient access to behavioral health services,” explains group project leader, Seneca Harberger. It is just one contribution to a wide array of ambitious projects taken on by organizations like 211 Palm Beach and the Southeast Behavioral Health Network. This project will undoubtedly require many cycles of feedback and improvement, but the team is hopeful that it will help close a gap they identified.

Dr. Jamian is dual Board Certified in Internal Medicine and Rheumatology. She completed her Internal Medicine residency at Cleveland Clinic Florida and her Rheumatology fellowship at Vanderbilt University Medical Center.

Share article on social media or email:

DynaMed® and DynaMedex™ Now Offering Maintenance of Certification (MOC) to American Board of Pediatrics (ABP) Board-Certified Pediatricians


News Image

By offering MOC to ABP-certified pediatricians, we look to support pediatricians on their path to clinical improvement, while assuring that pediatric patients are receiving optimal care.

American Board of Pediatrics (ABP) board-certified pediatricians can now earn Maintenance of Certification (MOC) through EBSCO Information Services’ (EBSCO) DynaMed® and DynaMedex™. These point-of-care tools are part of EBSCO’s Clinical Decisions support solutions, intended to improve patient outcomes by providing evidence-based information to physicians at the point of care.

ABP board-certified pediatricians may now earn Lifelong Learning and Self-Assessment (Part 2) MOC points when using DynaMed and DynaMedex. These self-assessment points support pediatricians to stay current with the latest clinical knowledge and help them assess and improve their skills. To earn MOC points for internet point-of-care activity through DynaMed and DynaMedex, pediatricians can easily set up an account, complete continuing medical education (CME) activity at their convenience, and credits are reported to the ABP.

DynaMed Senior Deputy Editor Scott Barron, MD, FAAP, says this added feature supports pediatricians in their quest for continuous learning. “In today’s world of ever-changing information and clinical knowledge, it can be challenging for physicians to find time to stay current with continuing medical education credits. By offering MOC to ABP-certified pediatricians, we look to support pediatricians on their path to clinical improvement, while assuring that pediatric patients are receiving optimal care.”

Pediatric Associates Family of Companies Pediatrician Dr. Fabiana H. Izquierdo says she is very excited and pleased to know that from now on, any board-eligible or certified pediatrician who uses DynaMed or DynaMedex can obtain ABP MOC Part 2 points. “I am thankful for how receptive the ABP and DynaMed were, and how quickly they made this happen. I hope this improvement helps pediatricians become, or remain, board certified.”

To learn more about DynaMed CE, visit: https://www.dynamed.com/cme-about.

About DynaMedex™

DynaMedex is a solution for clinical care teams that combines DynaMed® disease evidence from EBSCO Information Services (EBSCO) and Micromedex® drug evidence from Merative™. Learn more at dynamedex.com.

About EBSCO Information Services

EBSCO Information Services (EBSCO) is the preeminent provider of online research content and search technologies serving academic, school and public libraries; healthcare and medical institutions; corporations; and government agencies around the world. EBSCO’s Clinical Decisions suite of products are designed to improve patient care by providing healthcare professionals with the most current, evidence-based answers to clinical questions as they arise at the point of care. For more information, visit the EBSCO website at: http://www.ebsco.com

###

For more information, please contact:

Jessica Holmes

Communications Director

jmholmes@ebsco.com

978-414-0420

Share article on social media or email:

American College of Lifestyle Medicine Adds Innovative Health Plan Blue Cross and Blue Shield of Vermont to its Corporate Roundtable


News Image

It is groundbreaking for health plans to recognize this powerful evidence-based, first-line approach to chronic disease treatment.

The American College of Lifestyle Medicine (ACLM) has announced the addition of the progressive health plan Blue Cross and Blue Shield of Vermont to its Lifestyle Medicine Corporate Roundtable, a group of thought leaders and industry professionals who explore effective clinical innovations, activate marketing strategies, accelerate reimbursement and policy adoption, and pursue research and demonstrations of lifestyle medicine in practice. ACLM launched its Corporate Roundtable in 2016 and it now includes nearly 50 active member organizations in the lifestyle medicine ecosystem.

Lifestyle medicine is a medical specialty that uses therapeutic lifestyle interventions as a primary modality to treat chronic conditions including, but not limited to, cardiovascular diseases, type 2 diabetes, and obesity. Lifestyle medicine certified clinicians are trained to apply evidence-based, whole-person, prescriptive lifestyle change to treat and, when used intensively, often reverse such conditions. Applying the six pillars of lifestyle medicine—a whole-food, plant-predominant eating pattern, physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connections— also provides effective prevention for these conditions.

“Lifestyle medicine is a solution to improve patient outcomes, lower costs, improve patient experience, improve provider experience and address health equity,” said ACLM President Cate Collings, MD, FACC, DipABLM. “It is groundbreaking for health plans to recognize this powerful evidence-based, first-line approach to chronic disease treatment. We welcome Blue Cross and Blue Shield of Vermont to our Corporate Roundtable.”

As the state’s only local, not-for-profit health plan, the goal at Blue Cross and Blue Shield of Vermont is to help its members live healthier, more active lives. For over 30 years, the organization has been enhancing the health and well-being of the Vermonters they serve by offering innovative benefits to individuals, older Vermonters, and businesses.

The health plan is dedicated to finding new ways to support high-quality care, programs, and events that promote wellness, and now, lifestyle medicine. This new partnership will enable the expansion of lifestyle medicine programs and training throughout their clinical network in Vermont.

“As a health plan, we are working diligently to offer lifestyle medicine and support our members with interventions that, over decades of research and published literature, have been proven to change the trajectory of one’s health outcomes,” said Don George, President and CEO of Blue Cross and Blue Shield of Vermont. “This gives patients the tools and education to become their own health advocate and champion. We are pleased to collaborate with the American College of Lifestyle Medicine Corporate Roundtable in support of educating, empowering and engaging our members in positive health practices.”

ABOUT BLUE CROSS AND BLUE SHIELD OF VERMONT — As the state’s only local, not-for-profit health plan, the goal at Blue Cross and Blue Shield of Vermont is to help their members live healthier, more active lives. For over 30 years, the organization has been enhancing the health and well-being of the Vermonters they serve by offering innovative benefits to individuals, older Vermonters, and businesses. Blue Cross employees are dedicated to finding new ways to support high-quality care, programs, and events that promote wellness. Blue Cross and Blue Shield of Vermont is located in Berlin, Vermont. For more information about Blue Cross and Blue Shield of Vermont, visit bluecrossvt.org.

ABOUT ACLM — The American College of Lifestyle Medicine is the nation’s medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health. ACLM educates, equips, empowers and supports its members through quality, evidence- based education, certification and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management. Learn more at lifestylemedicine.org.

Share article on social media or email:

TouchPoint One Wins CUSTOMER Magazine 2022 Contact Center Technology Award


News Image

“Advanced analytics fuel Acuity’s complete suite of coaching, incentive, gamification, and business process modules and empower contact centers to lead with clarity, empathy, agility, and confidence.” Greg Salvato, CEO of TouchPoint One

TouchPoint One, the leading provider of employee engagement and performance management solutions for contact centers, announced today that its Acuity Performance Management platform has received the 2022 TMC Contact Center Technology Award from CUSTOMER Magazine. Acuity is distinguished for its behavioral analytics, gamification, and other employee experience innovations that transform contact center operations and enable employee, employer, and customer success.

“Acuity equips every member of the customer contact workforce with a deep, holistic view of performance outcomes as well as real-time insight and guidance regarding the processes, behaviors, and routines on which success is dependent,” said Greg Salvato, CEO of TouchPoint One. “Advanced analytics fuel Acuity’s complete suite of coaching, incentive, gamification, and business process modules and empower contact centers to lead with clarity, empathy, agility, and confidence. We thank our clients for their support and TMC and CUSTOMER Magazine for recognizing Acuity with the 2022 Contact Center Technology Award.”

Acuity is an advanced contact center performance management platform that collects, generates, and synthesizes disparate systems data to fuel an integrated suite of specialized business tools. Acuity offers real-time dashboards, departmental/functional scorecards, quality monitoring, agent coaching, virtual meeting & screen share, performance review, chat & email, analytics & reporting, and multiple gamification options delivered in a cloud-based SaaS platform.

“Congratulations to TouchPoint One for being awarded a 2022 CUSTOMER Magazine Contact Center Technology Award. Acuity has been selected for demonstrating innovation, quality and unique features that have positively impacted the customer experience,” said Rich Tehrani, CEO of TMC. “We’re pleased to recognize their achievement.”

This 17th-annual Contact Center Technology Award, presented by CUSTOMER Magazine, honors vendors and technologies that have embraced technology as a key tool for customer service excellence. This award distinguishes their success as innovators, thought leaders, and market movers in the contact center and customer care industries.

Acuity enables the digital transformation of performance management and employee engagement so that customer contact organizations can better understand their operations, improve organizational alignment, enhance both the employee and customer experience, and drive progressively enhanced financial and operational performance. Contact center leaders choose Acuity for its documented record of fixing attrition, absenteeism, performance, and engagement challenges and reducing operational expense.

To learn more about Acuity and TouchPoint One, visit the TouchPoint One website. Please also follow us on Twitter @TouchPoint_One and LinkedIn.

About CUSTOMER Magazine

Since 1982, CUSTOMER magazine has been the voice of the call/contact center, CRM, and teleservices industries. Through a combination of outstanding and cutting-edge original editorial, industry voices, in-depth lab reviews and the recognition of the innovative leaders in management and technology through our highly valued awards, CUSTOMER strives to continue to be the publication that holds the quality bar high for the industry. Please visit https://www.customer.tmcnet.com.

About TouchPoint One

TouchPoint One is the leading provider of contact center employee engagement and performance management solutions. The Company’s Acuity product is a full-featured contact center performance management platform that enables improved decision-making, talent development, and process execution at every operational level. TouchPoint One customer contact solutions deliver the rich benefits of employee dashboards, balanced scorecards, gamification, and advanced performance management through innovative design and functional alignment with business processes and strategies. http://www.touchpointone.com

TouchPoint One, Acuity, Sidekick, and A-GAME are registered trademarks of TouchPoint One, LLC. All other registered or unregistered trademarks are the sole property of their respective owners. © 2022 TouchPoint One, LLC. All rights reserved.

Share article on social media or email: